Pediatric Clinical Trials Market Report 2026

The pediatric clinical trials market size has grown strongly in recent years. It will grow from $18.38 billion in 2025 to $19.75 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to limited pediatric-specific drug research, reliance on adult trial data, ethical and regulatory challenges, low patient recruitment rates, minimal use of advanced analytics in trial design.

The pediatric clinical trials market size is expected to see strong growth in the next few years. It will grow to $26.67 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growing demand for pediatric-specific therapies, increasing adoption of digital and ai tools, rising regulatory incentives for pediatric studies, growing collaboration between pharma and research institutes, increasing focus on patient-centric and personalized clinical trials. Major trends in the forecast period include increasing adoption of precision medicine in pediatric clinical trials, rising use of ai and digital tools for trial design and data analysis, growing integration of real-world evidence in pediatric studies, increasing investment in pediatric drug development, rising focus on personalized and age-specific therapeutics.

The increasing incidence of pediatric cancer cases is expected to drive the growth of the pediatric clinical trials market in the coming years. Pediatric cancer refers to cancers that occur in children and adolescents under the age of 14. These cancers are relatively rare, and their patterns of growth and spread often differ from those seen in adult tumors. Pediatric clinical trials play a vital role in improving treatment approaches and patient prognosis by evaluating new therapies specifically designed for children. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization, it was estimated that approximately 9,910 children under the age of 15 in the United States would be diagnosed with cancer, and about 1,040 children in the same age group were expected to die from cancer in 2023. Therefore, the rising number of pediatric cancer cases is contributing to the growth of the pediatric clinical trials market.

Major companies operating in the pediatric clinical trials market are increasingly emphasizing collaborations and partnerships to deliver reliable and efficient services. Strategic partnerships involve structured relationships between two or more organizations, typically formalized through business agreements or contracts. For example, in September 2023, Strados Labs, a US-based developer of smart biosensors for respiratory monitoring, partnered with Ann & Robert H. Lurie Children’s Hospital, a US-based pediatric acute care hospital, to conduct a clinical trial evaluating the RESP Biosensor. The RESP Biosensor is a wearable device that uses acoustic sensing technology to monitor lung sounds associated with asthma symptoms such as coughing and wheezing. The objective of the trial is to assess the device’s effectiveness in accurately detecting and monitoring asthma exacerbations in pediatric patients.

In March 2024, PCM Trials, a US-based provider of mobile research nurse services for decentralized clinical trials, acquired EmVenio Research for an undisclosed amount. Through this acquisition, PCM Trials aims to expand its patient-centric and decentralized clinical trial model, enhancing participant recruitment and retention, particularly among underrepresented minority populations. EmVenio Research is a US-based company focused on improving access to pediatric clinical trials, especially for diverse and underserved communities.

Major companies operating in the pediatric clinical trials market are Medpac Inc., Pharmaceutical Product Development Inc., ICON plc, Syneos Health Inc., QPS Holdings LLC, Pfizer Inc., IQVIA Inc., Premier Research, Labcorp - Laboratory Corporation of America Holdings, The Emmes Company LLC, Synteract Inc., Charles River Laboratories International Inc., Covance Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, BioNTech SE, Moderna Inc., Parexel International Corporation, PRA Health Sciences, Wuxi AppTec, Merck & Co. Inc., AstraZeneca plc, Sanofi S.A., Johnson & Johnson, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, C.H. Boehringer Sohn AG & Co. KG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Oracle Health sciences.

North America was the largest region in the pediatric clinical trials market in 2025. The regions covered in the pediatric clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pediatric clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pediatric clinical trials market by increasing costs for imported trial equipment, laboratory supplies, and specialized pediatric devices, particularly in North America and Europe. Higher import duties have led to delays in trial initiation and increased operational expenses for contract research organizations and hospitals. However, tariffs have also incentivized local manufacturing of clinical trial materials and devices, promoting domestic innovation and reducing dependency on international suppliers.

The pediatric clinical trials market research report is one of a series of new reports that provides pediatric clinical trials market statistics, including pediatric clinical trials industry global market size, regional shares, competitors with a pediatric clinical trials market share, detailed pediatric clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric clinical trials industry. This pediatric clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pediatric clinical trials are research studies conducted to evaluate the safety, effectiveness, and appropriate dosage of pharmaceuticals, medical devices, and other therapeutic interventions in children. These trials are critical for developing age-appropriate, scientifically validated treatments and procedures that help determine and enhance the most effective medical therapies for pediatric patients.

The primary phases of pediatric clinical trials include phase I, phase II, phase III, and phase IV. Phase I trials mainly aim to assess the safety and dosage range of a new medication, typically involving about 20 to 100 healthy volunteers. The studies employ various designs, including interventional treatment studies and observational studies, and are carried out across multiple therapeutic areas such as infectious diseases, oncology, autoimmune or inflammatory diseases, respiratory disorders, mental health disorders, and others.

The pediatric clinical trials market includes revenues earned by entities through clinical research services, consulting, outsourcing services, and medical communications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.